About Abby Tyler
Abby Tyler is the Head of Immunoassay R&D, known for leading the development of widely utilized multiplexed immunoassays and currently focusing on ovarian cancer diagnostic tests.
Known information
Abby Tyler serves as the Head of Immunoassay Research and Development, where she has made significant contributions to the field of immunoassay development. With a robust educational background, holding degrees in Chemical and Biological Engineering from Utah State University and the University of Colorado at Boulder, Abby has utilized her analytical thinking to spearhead creative and effective solutions in immunoassay development. Throughout her career, she has developed and supervised the creation of numerous immunoassays. Notably, she led projects on multiplexed immunoassay development that have since become essential research products. Currently, Abby is applying her expertise to develop advanced diagnostic tests for ovarian cancer at AOA.
About AOA Dx
AOA Dx, headquartered in New York, NY, and Cambridge, MA, is a healthcare company specializing in early cancer detection technologies, particularly focusing on ovarian cancer through innovative blood tests like GlycoLocate™ and AKRIVIS GD™.